Close
ACHEMA MIDDLE EAST 2026

EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

PRAC, EMA's safety committee, has completed its review of pholcodine-containing medications used to treat nonproductive (dry) cough in adults and children as well as...

Launch of The First Pipeline Assessment By Vaccines Europe

With 100 vaccine candidates as of July 2022, Vaccines Europe has released its first pipeline evaluation of the 15 firms that make up its...

Non-Vaccine mRNA Therapeutics To Earn $2 Billion By 2028

A recent analysis from GlobalData estimates that by 2028, the approval of pipeline drugs will earn over $2 billion from five marketed messenger RNA...

Redesigning The Human Medicines Directive And Regulation

What changes are in store for the European Human Medicines Directive and Regulation when it is amended at the end of 2022? The current European...

AI Customizes Synthesized DNA For Medication Development

Researchers at Chalmers University of Technology in Sweden have created synthetic DNA that directs the cellular creation of proteins with the aid of an...

Start of A Multi-Drug Trial For Precision Medicine Cancer

A multi-drug, precision medicine trial involving Roche, the University of Manchester, and Cancer Research UK has begun for patients with rare cancers who need...

A Single, Linked Foundation Is Transforming Digital Trials

Clinical trials have expanded from 2,119 in 2000 to over 409,000 in 2022 (and counting). Not only has the number of trials increased, but...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...